PCI Biotech: Invitation to first-half year 2022 results presentation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Oslo, Norway, 26 August 2022 – PCI Biotech (OSE: PCIB) invites to an online presentation of the company’s first-half year 2022 interim report on Wednesday 31 August 2022, 08:30am – 09:30am CEST (local time).

The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session.

PCI Biotech’s first-half year 2022 interim report will be released on 31 August 2022 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

For further information, please contact:
Ronny Skuggedal, Interim CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech        
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo            

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Staff

Recent Posts

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

5 hours ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

5 hours ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

5 hours ago

Infisical Secures $16M Series A to Redefine Enterprise Secrets, Identity, and Access Management

Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…

5 hours ago

Choctaw Nation and Healthy Together Launch Streamlined Summer EBT Program in Just Six Weeks

MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…

5 hours ago

Improved Pharma Expands Footprint at Kurz Purdue Technology Center, Now Occupying Over 5,500 Square Feet

Fifth expansion since 2020 reflects growing demand for advanced pharmaceutical analysis and development services. WEST…

5 hours ago